SERUM LEVELS OF TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) AND SOLUBLE TNF RECEPTORS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION - CORRELATIONS TO CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL PARAMETERS

被引:271
作者
AUKRUST, P
LIABAKK, NB
MULLER, F
LIEN, E
ESPEVIK, T
FROLAND, SS
机构
[1] UNIV OSLO,NATL HOSP,MED DEPT A,CLIN IMMUNOL & INFECT DIS SECT,OSLO,NORWAY
[2] UNIV OSLO,NATL HOSP,KAPTEIN W WILHELMSEN & FRUES INST BACTERIOL,OSLO,NORWAY
[3] UNIGEN,CTR MOLEC BIOL,TRONDHEIM,NORWAY
[4] UNIV TRONDHEIM,INST CANC RES,TRONDHEIM,NORWAY
关键词
D O I
10.1093/infdis/169.2.420
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two EIAs (Medgenix and Quantikine) and a bioassay were used to measure tumor necrosis factor-alpha (TNF alpha) in serum samples from 73 human immunodeficiency virus type 1 (HIV-1)-seropositive patients and in samples from 2 control groups. All clinical groups of HIV-l-infected patients, regardless of concurrent illness, had significantly elevated levels of both types of soluble TNF receptors (sTNFRs) and immunoreactive TNF alpha (Medgenix EIA), with the highest concentrations among the AIDS patients. These TNF parameters were significantly correlated with reduced CD4(+) lymphocyte counts. Only a few HIV-1-infected patients had detectable TNF alpha levels measured by the Quantikine EIA. TNF alpha bioactivity was significantly raised only in the AIDS group. Serially measured sTNFRs, expressed as sTNFR slopes, were significantly associated with survival in the patient group. The raised levels of immunoreactive TNF alpha and sTNFRs strongly indicate activation of the TNF alpha system during HIV-1 infection. Levels increase with disease progression and degree of immunodeficiency; thus, serially measured sTNFRs may give useful prognostic information in HIV-1 infection.
引用
收藏
页码:420 / 424
页数:5
相关论文
共 15 条
  • [1] STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS
    ADERKA, D
    ENGELMANN, H
    MAOR, Y
    BRAKEBUSCH, C
    WALLACH, D
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) : 323 - 329
  • [2] BRINCHMANN JE, 1988, CLIN EXP IMMUNOL, V71, P182
  • [3] ENGELMANN H, 1990, J BIOL CHEM, V265, P1531
  • [4] A HIGHLY SENSITIVE CELL-LINE, WEHI-164 CLONE 13, FOR MEASURING CYTOTOXIC FACTOR TUMOR-NECROSIS-FACTOR FROM HUMAN-MONOCYTES
    ESPEVIK, T
    NISSENMEYER, J
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (01) : 99 - 105
  • [5] SOLUBLE RECEPTORS FOR TUMOR-NECROSIS-FACTOR - A PUTATIVE MARKER OF DISEASE PROGRESSION IN HIV-INFECTION
    GODFRIED, MH
    VANDERPOLL, T
    JANSEN, J
    ROMIJIN, JA
    SCHATTENKERK, JKME
    ENDERT, E
    VANDEVENTER, SJH
    SAUERWEIN, HP
    [J]. AIDS, 1993, 7 (01) : 33 - 36
  • [6] GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E
  • [7] SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR - INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS ACTIVATION
    HOWARD, OMZ
    CLOUSE, KA
    SMITH, C
    GOODWIN, RG
    FARRAR, WL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (06) : 2335 - 2339
  • [8] SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTORS (STNF-R) AND HIV-INFECTION - CORRELATION TO CD8+ LYMPHOCYTES
    KALINKOVICH, A
    LIVSHITS, G
    ENGELMANN, H
    HARPAZ, N
    BURSTEIN, R
    KAMINSKY, M
    WALLACH, D
    BENTWICH, Z
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1993, 93 (03) : 350 - 355
  • [9] ELEVATED LEVELS OF CIRCULATING CACHECTIN TUMOR NECROSIS FACTOR IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME
    LAHDEVIRTA, J
    MAURY, CPJ
    TEPPO, AM
    REPO, H
    [J]. AMERICAN JOURNAL OF MEDICINE, 1988, 85 (03) : 289 - 291
  • [10] LANTZ M, 1990, Cytokine, V2, P402, DOI 10.1016/1043-4666(90)90048-X